HCS PHARMA
HCS PHARMA is a French life-sciences company that develops BIOMIMESYS®, a patented 3D cell culture technology for drug discovery and disease modeling, while also operating a multilingual 9-country peptide review and affiliate-referral platform routing consumer demand to partner suppliers.
- Company typePrivate
- Founded2014
- HeadquartersLoos, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What HCS PHARMA does
HCS PHARMA is a privately-held life-sciences company founded in 2014 and headquartered in Loos, France, with a stated headcount of 1-10 employees. The company's core proprietary technology is BIOMIMESYS®, a patented 3D cell culture platform built on the Hydroscaffold™ system, which combines the structural properties of solid scaffolds with the dynamic characteristics of hydrogels. Matrices are composed primarily of Hyaluronic Acid, collagens, and adhesion proteins, with tunable Elastic Modulus, porosity, and density enabling recreation of tissue-specific microenvironments (liver, brain, heart, bone, skin) for drug discovery, disease modeling, tissue engineering, and cell therapy research applications.
Separately, the company operates hcs-pharma.com, a multilingual peptide review and rating platform spanning 9 country editions (UK, Netherlands, France, US, Sweden, Australia, Germany, Denmark, Austria). The site publishes structured five-criterion supplier evaluations, third-party laboratory test results (notably from Janoshik Analytical), and country-specific peptide guides covering products such as Retatrutide, Semaglutide, Tirzepatide, Cagrisema, Cagrilintide, Ipamorelin, NAD+, MOTS-c, Semax, Melanotan 1, BPC-157, TB-500, and LL-37. The platform distributes exclusive affiliate discount codes (HCS-P1-10, RETA20) that route consumer demand primarily to partner supplier LeoLab across multiple geographies.
HCS Pharma's business model combines two distinct revenue mechanics: (1) affiliate referral commissions generated when visitors click through to partner peptide suppliers and complete purchases, and (2) BIOMIMESYS® product sales targeted at biomedical research and drug development laboratories. The company has raised approximately $26M across disclosed funding rounds (notably a 2021 round led by The Global Emerging Markets Group and a 2022 follow-on), with early backing from Eurasante. Pricing for BIOMIMESYS® is not publicly disclosed, and no revenue figures have been made available.
HCS PHARMA firmographics
Firmographics- Name
- HCS PHARMA
- Legal name
- HCS Pharma
- Website
- https://hcs-pharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- HCS PHARMA is a French life-sciences company that develops BIOMIMESYS®, a patented 3D cell culture technology for drug discovery and disease modeling, while also operating a multilingual 9-country peptide review and affiliate-referral platform routing consumer demand to partner suppliers.
- Ownership category
- akta.pro rank
HCS PHARMA industry classification
Industry- Product category
- 3D Cell Culture Technology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Cellomics & High-Content Screening (HCS) Services (HLAGANAD)
- akta.pro secondary industries
- Compounding Pharmacy & Sterile Prep Workflow Systems (HLACAKAM), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)
Keywords
Where HCS PHARMA is headquartered
LocationHeadquarters
- HQ city
- Loos
- HQ country
- France
- HQ region
- Europe
Markets served
HCS PHARMA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Affiliate Referral Commissions: HCS Pharma's primary revenue stream is affiliate referral commissions earned when site visitors click through to partner peptide suppliers (notably LeoLab across multiple country sites) and complete purchases. The site acts as a content discovery and conversion layer, with discount codes (HCS-P1-10 for 10% off; RETA20 for £20 off Retatrutide 10mg) tracked back to HCS Pharma.
- BIOMIMESYS® 3D Cell Culture Product Sales: HCS Pharma also develops and supplies BIOMIMESYS®, a patented 3D cell culture product line targeted at biomedical research and drug development customers. Revenue mechanics are not publicly disclosed but the product is positioned for laboratory/research procurement.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | HCS-P1-10 promo code: 10% off orders at LeoLab partner suppliers |
| Other | Pay-as-you-go | RETA20 promo code: £20 off Retatrutide 10mg |
| Unit Pricing | Pay-as-you-go | Referenced peptide pricing at partner supplier LeoLab UK |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
HCS PHARMA product offering
Product offeringCore offering
HCS Pharma develops and supplies BIOMIMESYS®, a patented 3D cell culture technology built on its proprietary Hydroscaffold™ platform that combines solid scaffold properties with hydrogel characteristics to recreate human extracellular matrix. Matrices are composed of Hyaluronic Acid, collagens, and adhesion proteins, with tunable physical properties for drug discovery, disease modeling, tissue engineering, and cell therapy applications. The company also operates a multilingual peptide review and rating website (hcs-pharma.com) covering 9 country markets, routing purchase traffic to partner peptide suppliers via affiliate links and exclusive discount codes.
Product overview
HCS PHARMA operates as a peptide information, review, and rating platform (hcs-pharma.com) that independently evaluates third-party peptide suppliers across multiple markets (UK, US, Netherlands, France, Sweden, Australia, Germany, Denmark, Austria). The site's core offering is its proprietary BIOMIMESYS® 3D cell culture product line built on the patented Hydroscaffold™ technology, which combines scaffold and hydrogel properties to recreate human extracellular matrix for drug discovery, disease modeling, tissue engineering, and cell therapy applications. Beyond BIOMIMESYS®, HCS PHARMA publishes detailed review and rating pages for individual peptides including Retatrutide, Semaglutide, Tirzepatide, Cagrisema (a combination peptide of Cagrilintide and Semaglutide), Cagrilintide, Ipamorelin, NAD+, MOTS-c, Semax, Melanotan 1, Survodutide, BPC-157, TB-500, and LL-37, along with ancillary products like Bacteriostatic Water. The platform distributes exclusive discount codes (such as RETA20 and HCS-P1-10) for purchases through partner peptide suppliers such as LeoLab UK, and surfaces independent third-party lab testing results (e.g., Janoshik Analytical) to verify peptide purity. HCS PHARMA also provides localized versions of its review content across nine language/market editions.
Differentiator
Problem solved
Functional benefit
Brands
- BIOMIMESYS: Patented 3D cell culture technology combining properties of solid scaffolds and hydrogels, using Hydroscaffold technology with Hyaluronic Acid-based matrices for biomedical research applications.
Products and services
- BIOMIMESYS® 3D Cell Culture Matrices BIOMIMESYS® is a patented 3D cell culture technology that combines the properties of solid scaffolds and hydrogels to recreate the human extracellular matrix. Built on the proprietary Hydroscaffold™ platform, it uses Hyaluronic Acid, collagens, and adhesion proteins to mimic various tissue microenvironments (liver, brain, heart, bone, skin) with tunable physical properties. Designed for biotech and pharmaceutical researchers conducting drug discovery, disease modeling, tissue engineering, and cell therapy research who need more physiologically relevant in vitro models than traditional 2D cultures.
Quantifiable outcome
- Semaglutide 5mg (LeoLab) third-party tested at 99.981% purity by Janoshik Analytical (task 53115, batch G59785, 22 Nov 2024)
- +3 more outcomes
Companies that use HCS PHARMA
Customer profileSegments5 records
Ideal customer profiles2 records
HCS PHARMA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
HCS PHARMA partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered flagship, core and minor.
- LeoLabflagshipLeoLab is HCS Pharma's primary channel partner, featured as the top-rated UK peptide supplier with affiliate referral links from every UK edition peptide page (Retatrutide, Semaglutide, Tirzepatide, Cagrisema, Cagrilintide, Ipamorelin, and others) to leolab.uk. HCS Pharma distributes two exclusive discount codes for LeoLab: HCS-P1-10 (10% off all orders) and RETA20 (£20 off Retatrutide 10mg). Third-party testing verification from Janoshik Analytical is published on HCS Pharma's site for LeoLab products (e.g., Semaglutide 99.981% purity, Tirzepatide 99.776%, Cagrilintide 99.516%).
- LeoLab (EU country variants: leolab-shop.com, leolabshop.com, leolab.se)flagshipLeoLab's regional storefronts (leolab-shop.com, leolabshop.com, leolab.se) serve as the destination affiliate links across HCS Pharma's NL, FR, DE, DK, SE, and AT editions. Each country-localized peptide page (Retatrutide, Tirzepatide, Cagrisema, Cagrilintide, Semaglutide, Survodutide) routes to the appropriate LeoLab country storefront.
- LeoLab Rx (leolabrx.com)coreLeoLab Rx (leolabrx.com) is the US-edition affiliate destination for HCS Pharma's en-us site. Each peptide page (Retatrutide, Tirzepatide, Cagrisema, Cagrilintide, Survodutide) links to the LeoLab Rx US storefront.
- LeoLab Australia / South Africa storefronts (leolabpeptides.com, shop.leolab.co.za)coreLeoLab's Australian (leolabpeptides.com) and South African (shop.leolab.co.za) storefronts are the affiliate destinations for HCS Pharma's en-au edition. Peptide pages link to these regional storefronts for Retatrutide, Tirzepatide, Cagrisema, Cagrilintide, Survodutide, and TB-500.
- Bachem, Biosynth, Eurogentec, Bio-Connect (Netherlands)minorFeatured peptide brands in HCS Pharma's NL edition ranking for trusted Dutch peptide suppliers, highlighted for strict production controls, certification (Bachem, Biosynth, Eurogentec), and distributor reputation (Bio-Connect, LeoLab).
- ProteoGenix, Biolab Shop, Vital Proteins, Nutripure, SB-PEPTIDE (France)minorFeatured peptide brands in HCS Pharma's FR edition ranking for trusted French peptide suppliers, highlighted for scientific expertise, traceability (ProteoGenix, Biolab Shop), collagen-based peptide products (Vital Proteins), French natural-quality focus (Nutripure), and scientific orientation (SB-PEPTIDE).
- Core Peptides, Phoenix Pharmaceuticals, GenScript, Aapptec Peptides (US)minorFeatured US peptide brands in HCS Pharma's en-us edition ranking, recognized for verifiable purity data, third-party lab testing, consistent service, and reliable delivery across the US market.
- Nordic Biosite, Kronans Apotek (Sweden)minorFeatured Swedish peptide brands in HCS Pharma's sv-se edition ranking, recognized for consistent product quality, clear communication (Nordic Biosite), and customer service / product traceability (Kronans Apotek).
- Auspep, EHPlabs, PHYX Peptides (Australia)minorFeatured Australian peptide brands in HCS Pharma's en-au edition ranking alongside LeoLab, recognized for industry presence, customer reviews, professional reputation, and compliance with local standards.
- Biolab Shop, Shop Aphoteke, BPS Pharma, Biomol GmbH (Germany)minorFeatured German peptide brands in HCS Pharma's de-de edition ranking, recognized for strict quality standards, transparent product information, certified purity, and professional service.
- Orifarm, 2care4 ApS, Apotek Dansk, Sikkert Vægttab ApS (Denmark)minorFeatured Danish peptide brands in HCS Pharma's da-dk edition ranking, recognized for stability, transparency, and high European production standards.
- Biolabshop.de, Shop-apotheke.at (Austria)minorFeatured Austrian peptide brands in HCS Pharma's de-at edition ranking, alongside LeoLab, BPS Pharma, and Biomol GmbH, recognized for solid reputation as quality peptide sources.
- Peptagenix PeptidesminorReferenced as an alternative UK supplier of Tirzepatide 10mg vials at £180 each, with multibuy discounts (5% on 3 units, up to 20% on 6 units), mentioned in the HCS Pharma Tirzepatide review as an alternative to LeoLab.
- UK-Peptides Direct, Pure Peptides UK, Dr Peptides, XL Peptides (UK)minorListed alongside LeoLab as trusted UK peptide brands recognized for offering peptides that meet high purity standards, transparent testing, reliable shipping, and positive customer experiences within HCS Pharma's UK evaluation.
- National Institute for Health and Care Excellence (NICE)minorNICE (the UK health authority) logo is displayed in the footer of hcs-pharma.com across multiple country editions (UK, NL, FR, US, SE, AU, DE, DK, AT, Best Sellers page), suggesting a citation/credibility reference linked to nice.org.uk.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
HCS PHARMA competitors and assessment
Company assessmentBroad incumbents
- Sartorius: Bioprocessing and cell-line development vendor with growing cell-culture and cell-model offerings. Comparable as a broad incumbent serving similar biotech/pharma R&D customers with overlapping technology categories.
- Corning Life Sciences (Matrigel): Corning's Matrigel is the dominant ECM-mimetic basement-membrane matrix used in 3D cell culture, cancer biology, and stem-cell workflows. Directly comparable as a competing 3D/ECM scaffold technology targeting the same biomedical research customers as BIOMIMESYS®.
- Merck KGaA (Sigma-Aldrich / MilliporeSigma): MilliporeSigma sells ECM components, hydrogels, and 3D culture reagents used in drug discovery and tissue engineering — directly overlapping with BIOMIMESYS®'s hydroscaffold/hyaluronic-acid-based ECM applications.
- Thermo Fisher Scientific: Major life-sciences tools vendor offering Gibco cell-culture media, matrices, and 3D culture systems. Comparable as a broad incumbent with overlapping 3D cell culture and drug-discovery product portfolio that competes for the same biotech R&D budget.
- Lonza Group: Global CDMO and cell-and-gene-therapy solutions provider with extensive cell-culture product lines including primary cells, media, and 3D culture systems. Comparable as a broad incumbent in the cell-culture and drug-discovery tools space.
Emerging players
- CN Bio Innovations: Developer of organ-on-chip and microphysiological systems for drug discovery and disease modeling. Comparable as a smaller specialist in advanced in vitro models competing for similar 3D/organ-mimetic use cases as BIOMIMESYS®.
- Emulate Inc. Organ-on-chip platform company targeting preclinical drug-development workflows. Comparable as an emerging player in physiologically relevant in vitro models, competing with BIOMIMESYS® for tissue-specific 3D culture adoption.
- Mimetas: Organ-on-chip and 3D tissue model company (OrganoPlate) serving pharma toxicology and disease-modeling customers. Comparable as an emerging 3D cell-culture platform peer with similar disease-modeling positioning.
- TissUse: Multi-organ-chip and microphysiological systems company based in Europe. Comparable as a European emerging peer in the 3D/advanced in vitro model category with overlapping drug-discovery applications.
Direct peers
- Examine.com: Independent research-driven supplement and compound review site with affiliate monetization. Comparable as a content/affiliate peer for the peptide-review site business line, though without the BIOMIMESYS® biotech product overlap.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
HCS PHARMA social profiles
Digital presenceHCS PHARMA financial estimates
Financial estimateRevenue estimate
Valuation estimate
HCS PHARMA leadership team
Management profileNumber of profiles
Profiles1 record
HCS PHARMA funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HCS PHARMA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HCS PHARMA
What does HCS PHARMA do?
HCS Pharma develops and supplies BIOMIMESYS®, a patented 3D cell culture technology built on its proprietary Hydroscaffold™ platform that combines solid scaffold properties with hydrogel characteristics to recreate human extracellular matrix. Matrices are composed of Hyaluronic Acid, collagens, and adhesion proteins, with tunable physical properties for drug discovery, disease modeling, tissue engineering, and cell therapy applications. The company also operates a multilingual peptide review and rating website (hcs-pharma.com) covering 9 country markets, routing purchase traffic to partner peptide suppliers via affiliate links and exclusive discount codes.
Is HCS PHARMA a public or private company?
HCS PHARMA is a private company. It is classified as venture growth investor backed and is currently operating.
When was HCS PHARMA founded?
HCS PHARMA was founded in 2014. It employs 1 to 10 people.
Where is HCS PHARMA based?
HCS PHARMA is headquartered in Loos, France, in the Europe region.
How does HCS PHARMA make money?
Two revenue lines are on record. Affiliate Referral Commissions are the primary driver. The others are BIOMIMESYS® 3D Cell Culture Product Sales.
Who are HCS PHARMA's main competitors?
Broad incumbents on record are Sartorius, Corning Life Sciences (Matrigel), Merck KGaA (Sigma-Aldrich / MilliporeSigma), Thermo Fisher Scientific and Lonza Group. Emerging players are CN Bio Innovations, Emulate Inc., Mimetas and TissUse. Examine.com is listed as a direct peer.
Does HCS PHARMA have an API?
No public API is recorded for HCS PHARMA.
What industry is HCS PHARMA in?
HCS PHARMA's product category is 3D Cell Culture Technology. Its primary akta.pro industry code is HLAGANAD, Cellomics & High-Content Screening (HCS) Services, with a secondary code of HLACAKAM, Compounding Pharmacy & Sterile Prep Workflow Systems. Its NAICS code is 325414 and its SIC code is 2834.